Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2011-01-18
2011-01-18
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C424S400000
Reexamination Certificate
active
07872050
ABSTRACT:
A composition and method for treatment of cancer. The composition for treating a skin disorder, comprising: a Nitrogen Mustard or an HX salt of the Nitrogen Mustard, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier that does not include petrolatum or ethanol does not include petrolatum or ethanol. The method comprises topically applying the composition of a Nitrogen Mustard or a HX salt of the Nitrogen Mustard to the affected skin, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier does not include petrolatum or ethanol.
REFERENCES:
patent: 3767792 (1973-10-01), Cook et al.
patent: 3904766 (1975-09-01), Van Scott et al.
patent: 4083692 (1978-04-01), Epstein et al.
patent: 4206222 (1980-06-01), Valetas
patent: 4853388 (1989-08-01), Pearlman
patent: 4863910 (1989-09-01), Takayanagi
patent: 4888344 (1989-12-01), Sunagawa et al.
patent: 4888354 (1989-12-01), Chang et al.
patent: 4949641 (1990-08-01), Sayles
patent: 5051363 (1991-09-01), Ritter et al.
patent: 5229422 (1993-07-01), Takahashi et al.
patent: 5326790 (1994-07-01), Thornfelt
patent: 5719197 (1998-02-01), Kanios et al.
patent: 5820872 (1998-10-01), Edelson et al.
patent: 5824650 (1998-10-01), De Lacharriere et al.
patent: 5948437 (1999-09-01), Parikh et al.
patent: 5972892 (1999-10-01), De Lacharriere et al.
patent: 6005002 (1999-12-01), Springer et al.
patent: 6017902 (2000-01-01), Glass et al.
patent: 6124108 (2000-09-01), Ray
patent: 6255502 (2001-07-01), Penkler et al.
patent: 6329148 (2001-12-01), Rosen et al.
patent: 6472435 (2002-10-01), Boyle
patent: 6692742 (2004-02-01), Nakamura et al.
patent: 6753155 (2004-06-01), Ray
patent: 7323171 (2008-01-01), Wallner et al.
patent: 2002/0146692 (2002-10-01), Yamazaki et al.
patent: 2003/0083321 (2003-05-01), Lerner et al.
patent: 2003/0087961 (2003-05-01), Ko et al.
patent: 2005/0039228 (2005-02-01), Ding et al.
patent: 2007/0287719 (2007-12-01), Boyden et al.
patent: 2008/0194699 (2008-08-01), Alonso et al.
patent: 2010/0029783 (2010-02-01), Alonso et al.
patent: 2010/0041767 (2010-02-01), Alonso et al.
patent: 0317281 (1989-05-01), None
patent: WO8704154 (1987-07-01), None
patent: WO03037380 (2003-08-01), None
patent: WO2004050057 (2004-06-01), None
patent: WO 2006/099385 (2006-09-01), None
patent: WO 2009/120493 (2009-10-01), None
Bonina et al. “Vehicle effects on in vitro skin permation of and stratum corneum affinity for model drugs caffeine and testoterone” International journal of pharmaceutics, vol. 100, pp. 41-47 (abstract provided).
Kravitz, PH; McDonald, CJ “Topical nitrogen mustard induced carcinogenesis” Acta Derm Venereol., 1978, vol. 58, No. 5, pp. 421-425 (abstract provided).
Wormser et al. “Noninvasive procedure for in situ dertermination of skin surface aspartic proteinase activity in animals; implications for human skin” Arch Dermatol Res, 1997, vol. 289, pp. 686-691.
Liren Tang et al., “Topical Mechlorethamine Restores Autoimmune-Arrested Follicular Activity in Mice with an Alopecia Areata-Like Disease by Targeting Infiltrated Lymphocytes”, J. Investigative Derm., 120(3) 400-406 (2003).
P. Foulec et al., “Evaluation of a 1-h exposure time to mechlorethamine in patients undergoing topical treatment”, Brit. J. Derm. 147, 926-930 (2002).
Taylor, R.J: Halprin, K.M.: Levine, V.; Aoyagi, T. Mechlorethamine Hydrochloride Solutions and Ointment Prolonged Stability and Biological Activity, Archives of Dermatology, Jul. 1980, vol. 116(7), pp. 783-785.
Cummings, J., et al., “The Long Term Stability of Mechlorethamine Hydrochloride (Nitrogen Mustard) Ointment Measured by HPLC”, J. Pharm. Pharmacol. 45: 6-9 1993.
Price, Norman M., “Ointment-Based Mechlorethamine Treatment for Mycosis Fungoides”, Cancer, 52, 2214-2219 (1983).
Kim, Youn, H., “Topical Nitrogen Mustard in the Management of Mycosis Fungoides, Update of The Stanford Experience”, ARCH Dermatol, 139, 165-173 (Feb. 2003).
Youn H. Kim, MD; Gina Martinez, BA; Anna Varghese, BA; Richard T. Hoppe, MD, Topical Nitrogen Mustard in the Management of Mycosis Fungoides, Arch Dermatol. 2003;139:165-173.
Khan et al., “Hepatocyte toxicity of mechlorethamine and other alkylating anticancer drugs. Role of lipid peroxidation,” Biochem Pharmacol 43(9):1963-7 (1992).
Lessin et al., Testing efficacy and safety of topical nitrogen mustard in mycosis fungoides, submitted to 21stWorld Congress of Dermatology in Buenos Aires, Oct. 1-5, 2007.
Lessin, Nitrogen mustard (NM) ointment formulation containing propylene glycol (PG) is active in treating mycosis fungoides (MF), J Inv Dermatol, 2007 (abstract).
Ritschel, et al., Stability of the nitrogen mustard mechlorethamine in novel formulations for dermatological use, Int'l J. Pharm., 362: 67-73, 2008.
Wu et al., “Elucidation of the chemical structures of natural antioxidants isolated from rosemary,” JAOCS 59(8):339-345 (1982).
Non-final office action mailed Feb. 19, 2010 in U.S. Appl. No. 11/908,531, currently under examination at the USPTO.
PCT/US2006/009060 International Search Report mailed Jan. 28, 2008.
PCT/US2009/036737 International Search Report mailed Jan. 11, 2010.
Alonso et al., U.S. Appl. No. 12/687,605, filed Jan. 14, 2010, entitled “Stabilized compositions of alkylating agents and methods of using same,” currently pending.
Mechlorethamine (Topical), Drugs.com, Drug information online www.drugs.com/mmx/mechlorethamine-hydrochloride.html, Jun. 14, 2010.
Chabner et al., “Antineoplastic agents,” Goodman & Gilman's The Pharmacological Basis of Therapeutics, Tenth Edition, Chapter 52, pp. 1389-1397, 2001.
Bell, “The effect of the solvent on protolytic equilibria,” The Proton in Chemistry, Second Edition (Cornell University Press) pp. 44-55, 1959.
Non-final office action mailed Jun. 10, 2010 in connection with U.S. Appl. No. 12/549,258.
Arrazola et al., “Treatment of alopecia areata with topical nitrogen mustard,” Int J Dermatol 24(9):608-10, 1985.
Bernardo et al., “Topical nitrogen mustard in the treatment of alopecia areata: a bilateral comparison study,” J Am Acad Dermatol 49(2):291-4, 2003.
Connors et al., “Mechlorethamine,” Chemical Stability of Pharmaceuticals. A Handbook for Pharmacists, Second Edition (John Wiley & Sons, Inc.) pp. 529-533, 1986.
Tang et al., “Topical mechlorethamine restores autoimmune-arrested follicular activity in mice with an alopecia areata-like disease by targeting infiltrated lymphocytes,” J Invest Dermatol 120(3):400-6, 2003.
Final office action mailed on Jul. 6, 2010 in connection with U.S. Appl. No. 11/908,531, under examination.
Alonso Robert
Crooks Peter A.
Pimley Mark A.
Carter Kendra D
Padmanabhan Sreeni
Wilson Sonsini Goodrich & Rosati PC
Yaupon Therapeutics Inc.
LandOfFree
Stabilized compositions of volatile alkylating agents and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stabilized compositions of volatile alkylating agents and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stabilized compositions of volatile alkylating agents and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2654036